X4 Pharmaceuticals(XFOR) - 2024 Q2 - Quarterly Results

Exhibit 99.1 X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates First U.S. commercial sales of XOLREMDI™ (mavorixafor) following April 2024 FDA approval Positive interim data from Phase 2 trial of mavorixafor in chronic neutropenia; full trial results expected in November 2024 Initiated global, pivotal Phase 3 trial of mavorixafor in chronic neutropenia Conference call to be hosted today at 8:30 a.m. ET BOSTON, August 8, 2024 – X4 Pharmaceuticals (Nasdaq: XFOR), ...